Selank & NA-Selank Amidate

Common side effects:

• Mild fatigue or lethargy following administration.
• Temporary injection site irritation if administered subcutaneously.
• Changes in taste or smell if administered intranasally.
• Mild headache during initial research applications.

Rare or serious side effects:

• Allergic reactions or hypersensitivity to the peptide sequence.
• Paradoxical anxiety or restlessness in certain animal models.
• Unintended interactions with other serotonergic or GABAergic compounds.

Neurotransmitter modulation is the primary mechanism by which the Selank & NA-Selank Amidate peptide exerts its anxiolytic and nootropic effects. It influences the concentration of monoamines like serotonin, dopamine, and norepinephrine in the brain, while also acting as an allosteric modulator of the GABA-A receptor to promote calmness. Furthermore, it inhibits the enzymes responsible for degrading enkephalins, naturally occurring peptides that regulate stress and pain responses. Neurotrophic and immunomodulatory pathways also play a crucial role in the efficacy of NA-Selank Amidate. The peptide significantly upregulates the expression of Brain-Derived Neurotrophic Factor (BDNF) in the hippocampus, which is essential for learning, memory, and neuroplasticity (Kozlovskiĭ et al., 2002). Additionally, as a tuftsin derivative, it retains the ability to stimulate macrophage activity and modulate interleukin levels, linking cognitive health with immune system homeostasis.

Discovery and development of Selank originated in the late 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences. Researchers sought to create a stable, synthetic analog of the naturally occurring tetrapeptide tuftsin by adding a sequence that prevents rapid enzymatic degradation. The addition of the N-acetyl and amidate groups in NA-Selank Amidate further enhanced the peptide's metabolic stability and ability to cross the blood-brain barrier. Regulatory status for Selank varies globally, though it is officially approved in Russia as a generalized anxiety disorder treatment. In the United States and most other countries, Selank & NA-Selank Amidate remain classified as research-only chemicals. They are not approved by the FDA for human consumption and are strictly utilized in laboratory settings to investigate their neuroprotective properties.